RKS-262

• CAS Number :

  1041469-97-9

• Target :

  Others

• Related Pathways :

  Others

• Bioactivity :

  RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI (60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI (50) :?~?10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI (50) ?>?1?µM) to RKS262 treatment.

• Smiles :

  ClC=1C=2C(OC(=O)C1C=NN3C(C)CS(=O)(=O)CC3)=CC=C(Br)C2

• Molecular Formula :

  C15H14BrClN2O4S

• Molecular Weight :

  433.7

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C